top of page

TREATMENT OF DOWN SYNDROME

Down Syndrome is one of the most complex genetic diseases compatible with human survival. The changes known so far cannot be cured - but they can be treated. Recognizing Down Syndrome as more than just a genetic issue opens the door for targeted research, but also for treatment. Downplaying this metabolic disease prevents children with Down Syndrome from living to their full developmental potential. The extensive, individual treatment of Down Syndrome is the main focus of my practice and a project close to my heart - born out of my love for my daughter. I use the extensive specialist knowledge that I have acquired as a biologist and my practical experience to provide the best possible support for each of my patients.

GENETICS AND METABOLISM OF DOWN SYNDROME

Down Syndrome is a congenital developmental disorder that occurs with an incidence of approximately 1:600 births worldwide. John Langdon H. Down described the disease in 1866 based on his observations in purely symptomatic terms. In 1959, Jérôme Lejeune was able to show that the cause of the disease lies in an extra copy of chromosome 21, which is why it is also referred to as trisomy 21

The sequence of chromosome 21 was published in 2000 and the approx. 225 genes described on it 1. It is now known that the effects of the extra chromosome 21 are not limited to this, but rather extend genome-wide 2,3,4. There are two ways of how the biochemistry of a person with Down syndrome is be influenced: On the one hand, it is assumed that a gene dosage effect is present (in trisomy 21, all genes on chromosome 21 are not present in duplicate, but in triplicate; this means that the synthesis rate for a gene product can reach 150% instead of 100%). On the other hand, there are a variety of epigenetic changes 5,6,7. These represent reversible changes in gene expression that are not based on an altered DNA sequence, but rather involve mechanisms such as DNA methylation and histone modifications. The human epigenome is theoretically flexible throughout our life using methylation of DNA, e.g. through environmental influences, medication and diet, but also through targeted interventions with nutritional supplements, so-called Nutraceuticals.

 

A treatment option for Down Syndrome is the so-called Targeted Nutritional Intervention (TNI), which attempts to balance the metabolic pathways that are altered by the extra genetic material. This applies, among other things, to the problem of systemic oxidative stress, folic acid metabolism and the methylation, collagen metabolism, the altered balance of neurotransmitters, as well as the premature development of the Alzheimer's dementia. All changes in biochemistry and metabolism ultimately lead to what we know as Down Syndrome. TNI treatment does not represent a cure and does not attempt to change the personality of the person affected with Down Syndrome, but rather to supplement the individual biochemical needs and thus reduce or stop the known secondary diseases. Given the neurodegenerative character of Down Syndrome, it makes sense that any treatment should be started as early as possible - but in principle treatment is possible at any time (prenatal, first years of life, adolescence).

CLINICAL RESEARCH ON DOWN SYNDROME

The common objection often heard against TNI is that there are not enough double-blind, randomized clinical studies as well as long-term studies on the treatment of Down Syndrome. However, some studies on this topic have been published 8,9,10,11,12,13,14, and in addition there are countless published peer-reviewed, mechanistic studies, as well as preclinical and translational studies that have shown positive effects of treatment and explain why a treatment for Down Syndrome is possible and important. The genetic and epigenetic complexity of Down Syndrome and the associated high individual variability make it clear that meaningful clinical studies in this area are difficult to carry out. Short-term studies with individual inhibitors or antioxidants are not enough to demonstrate significant positive effects, at least not as measurable changes in “intelligence” or “developmental milestones.” There are currently no clinical studies on today's extensive TNI protocol.

 

The best possible window for effective treatment is a prenatal development, as this is where early correction of the genetic imbalance can have the greatest impact 15. Treatment of trisomy 21 at a later point in time would require as many of the as possible critical genes of chromosome 21 and not just individual biochemical pathways. In addition, underlying diseases such as hypothyroidism would also have to be included in clinical studies, as these are often associated with trisomy 21 and have an intensive influence on child development 16,17.

RISKS OF TARGETED NUTRITIONAL INTERVENTION

Every medical and naturopathic treatment has its risks, but these should always be compared with the risks that may arise without treating the condition. The risks of TNI treatment are low compared to the known long-term damage of an extra 21st chromosome, especially if the blood is regularly checked to ensure that all important parameters are within the reference values, as I generally do in my practice. A 20-year follow-up study showed that over 97% of study participants with Down Syndrome develop dementia at an average age of diagnosis of 55 years 18. More recent studies show symptomatic Alzheimer's disease with a prevalence of 90-100% from the age of 60 onwards 19. The corresponding biomarkers of neuropathologies (Alzheimer's plaques and neurofibrils), however, can sometimes be detected in the brain much earlier (from the age of 20) 19 -  the premature aging and neurodegeneration, which occur in Down Syndrome, have been described in detail 20,21,22,23. However, individuals with Down Syndrome now have a significantly longer life expectancy due to better prenatal and perinatal care: in Europe it rose from an average of nine years (1929) to around 60 years (2004) and many people with Down Syndrome are now reaching the age of 70. The early development of Alzheimer's therefore represents a serious problem 24. Only through effective treatment or prevention of Alzheimer's disease could the life expectancy of people with Down Syndrome be further increased. 25 A number of studies have now shown that the cause of this is, at least in part, the increased rates oxidative stress 25,26,27, which occurs in individuals with Down Syndrome and which can be effectively reduced to normal levels by TNI 28.

 

It is critical to question whether comprehensive biochemical and metabolic treatment of trisomy 21 should be fundamentally rejected due to limited clinical trials, although the increasing number of pharmacological studies have so far had very little success in finding effective treatments to improve the quality of life of people with trisomy 21 29. The Functional medicine that I use in my practice can help to identify individual weak points in biochemistry and treatment with TNI can successfully compensate for these in order to prevent long-term damage. Treatment with TNI must always be individualized and appropriate blood tests should be carried out regularly. The necessary tests can all be carried out in my practice. In this way, the individual developmental potential can be maintained and the quality of life of families can be significantly increased.

1. Hattori M et al. The DNA sequence of human chromosome 21. Nature. 2000 May 18;405(6784):311-9.

2. Letourneau A. Domains of genome-wide gene expression dysregulation in Down's syndrome. Nature. 2014 Apr 17;508(7496):345-50.

3. Zhao Y. A microRNA cluster (let-7c, miRNA-99a, miRNA-125b, miRNA-155 and miRNA-802) encoded at chr21q21.1-chr21q21.3 and the phenotypic diversity of Down's syndrome (DS; trisomy 21 ). J Nat Sci. 2017 Sep;3(9). pii: e446.

4. Shapshak P. Molecule of the month: miRNA and Down's syndrome. Bioinformation. 2013; 9(15): 752–754.

5. Karmiloff-Smith A. et al, The importance of understanding individual differences in Down syndrome. Version 1. F1000Res. 2016; 5: F1000 Faculty Rev-389.

6. Dekker AD. et al, Epigenetics and Down Syndrome. Neuropsychiatric Disorders and Epigenetics, pp.163-184, 2016.

7. Henneman P et al. Widespread domain-like perturbations of DNA methylation in whole blood of Down syndrome neonates. PLoS One. 2018 Mar 30;13(3):e0194938.

8. de la Torre R. et al. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomized, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jul;15(8):801-810.
9. Yellow, MJ. Targeted Nutritional Intervention (TNI) for Children with Down Syndrome. Pediatric. Practice 59:703-708 (2001)
10. Mazurek D., Wyka J. Down syndrome--genetic and nutritional aspects of accompanying disorders. Rocz Panstw Zakl Hig. 2015;66(3):189-94.
11. Meguid et al. Antioxidant activity in Egyptian children with Down syndrome before and
after nutritional supplementation. J. Chem. Pharm. Res., 2015, 7(2):324-331
12. Miles MV. et al. Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. Pediatr Neurol. 2007 Dec;37(6):398-403.
13. Nachvak et al. α-Tocopherol supplementation reduces biomarkers of oxidative stress in children with Down syndrome: a randomized controlled trial. Your J Clin Nutr. 2014 Oct;68(10):1119-23.
14. Parisotto et al. Persistence of the benefits of an antioxidant therapy in children and teenagers with Down syndrome. Res Dev Disable. 2015 Oct-Nov;45-46:14-20.

15. Guedj et al. Prenatal treatment of Down syndrome: a reality? Curr Opin Obstet Gynecol. 2014 Apr;26(2):92-103.

16. King K et al. Thyroid dysfunction in children with Down syndrome: a literature review. Ir J Med Sci. 2014 Mar;183(1):1-6.

17. Capone GT. et al. Co-occurring medical conditions in adults with Down syndrome: A systematic review towards the development of health care guidelines. Am J Med Genet A. 2018 Jan;176(1):116-133.

18. McCarron M et al. A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res. 2017 Sep;61(9):843-852.

19. Fortea et al., Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study, Lancet. 2020 Jun 27; 395(10242): 1988–1997.

20. Franceschi et al. Accelerated bio-cognitive aging in Down syndrome: State of the art and possible deceleration strategies. Aging cells. 2019 Jun;18(3):e12903.

21. Lott. Neurological phenotypes for Down syndrome across the life span. Prog Brain Res. 2012;197:101-21.

22 Grieco et al. Down syndrome: Cognitive and behavioral functioning across the lifespan. Am J Med Genet C Semin Med Genet. 2015 Jun;169(2):135-49.

23. Perluigi et al. Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics. Proteomics Clin Appl. 2014 Feb;8(1-2):73-85.

24. Cipriani G. et al, Aging With Down Syndrome: The Dual Diagnosis: Alzheimer's Disease and Down Syndrome.Am J Alzheimers Dis Other Demen. 2018 Jun;33(4):253-262.

25. Iulita et al.,. Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. JAMA Network Open. 2022 May 2;5(5):e2212910.

26. Butterfield et al. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochem J. 2014 Oct 15;463(2):177-89. doi: 10.1042/BJ20140772.
27. Nunomura A. et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol. 2000 Nov;59(11):1011-7.
28. Zigman and Lott. Alzheimer's disease in Down syndrome: neurobiology and risk. Ment Retard Dev Disabil Res Rev. 2007;13(3):237-46.

29 Lott IT. Antioxidants in Down syndrome. Biochim Biophys Acta. 2012 May;1822(5):657-63.

30 Hart SJ. et al. Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: Strides to date. Am J Med Genet A. 2017 Nov;173(11):3029-3041.

bottom of page